Latest studies
- Ongoing, recruitingTherapeutic confirmatory (Phase III)
An Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of ZYN002 Administered as a Transdermal Gel to Children, Adolescents and Young Adults with Fragile X Syndrome
This study looks at the long-term safety of a CBD gel for children, teenagers, and young adults with Fragile X Syndrome. It also checks if the gel helps with common symptoms like irritability and social difficulties over time.
Fragile X Syndrome (FXS)Ireland - Active not recruitingPHASE1, PHASE2
Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
This study is looking at a new medicine called DYNE-251 for boys aged 4-16 with Duchenne Muscular Dystrophy (DMD). It aims to see if the medicine is safe, well-tolerated, and helps the body make more dystrophin protein.
Duchenne Muscular Dystrophy (DMD)Ireland - Active not recruitingPHASE4
Ultrasound-facilitated, Catheter-directed, Thrombolysis in Intermediate-high Risk Pulmonary Embolism
This study looks at treating blood clots in the lungs (pulmonary embolism). It compares standard blood thinners with a new treatment using blood thinners and a device that helps dissolve clots faster, to see which is safer and more effective.
Pulmonary EmbolismIreland - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, multicenter, open-label, randomized study to evaluate the efficacy and safety of fedratinib compared to best available therapy in subjects with DIPSS - intermediate or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis and previously treated with ruxolitinib
This study is comparing a new medicine, fedratinib, with other common treatments for people with a type of bone marrow disorder called myelofibrosis. It's for patients whose myelofibrosis has been treated before with another drug called ruxolitinib. We want to see how well fedratinib shrinks the spleen.
Primary myelofibrosispost-polycythemia vera myelofibrosisor post-essential thrombocythemia myelofibrosisIreland - RecruitingPHASE3
Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)
This study is looking at the safety of a new patch treatment, called Viaskin Peanut Patch (DBV712), for peanut allergy in very young children (1 to 3 years old). It aims to see if the patch is safe over six months, with some children receiving the patch and others a dummy patch.
AllergyPeanut AllergyIreland - Recruiting
E²-RADIatE: EORTC-ESTRO RADiotherapy InfrAstrucTure for Europe
The E²-RADIatE study is collecting information from cancer patients across Europe who are having radiotherapy. This helps researchers better understand how radiotherapy is used and how it works alongside other treatments to improve care for people with cancer.
CancerIreland - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
This study looks at a new drug called niraparib to see if it can help women with advanced ovarian cancer stay well longer after their first round of chemotherapy. It compares niraparib to a dummy pill to find out how effective and safe it is.
Homologous recombination deficiency advanced ovarian cancerIreland - Active not recruitingPHASE3
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
This study looks at a new drug, imlunestrant, for early breast cancer. It compares it to standard hormone treatments like tamoxifen, anastrozole, letrozole, and exemestane. The goal is to see if imlunestrant works better for patients whose cancer is at higher risk of returning.
Breast NeoplasmsIreland - Active not recruitingNA
Evaluation of Safety and Performance of the Omega™ LAA (Left Atrial Appendage) Occluder and Omega™ Delivery System in Patients With Non-Valvular Atrial Fibrillation and High Bleeding Risk
This study looks at a new device, the Omega LAA Occluder, designed to prevent strokes in people with a type of irregular heartbeat called non-valvular atrial fibrillation, especially if they have a high risk of bleeding. It checks how safe and effective the device is.
Non-Valvular Atrial FibrillationIreland - Ongoing, recruitingTherapeutic use (Phase IV)
Daily versus alternate day oral iron supplementation for the treatment of iron deficiency anaemia in pregnancy (IronMother)
This study is looking at the best way to give iron supplements to pregnant women who have too little iron (iron deficiency anaemia). We want to find out if taking iron every day or every other day works better to improve their iron levels and how they feel, while keeping side effects low.
Iron deficiency anaemia in pregnancyIreland - Ongoing, recruitingTherapeutic confirmatory (Phase III)
ATLAS-OLE: An Open-label, Long-term Safety and Efficacy Study of Fitusiran in Patients with Hemophilia A or B, with or without Inhibitory Antibodies to Factor VIII or IX
This study is testing a new medicine, fitusiran, for people with haemophilia A or B. It wants to see how safe and effective it is over a long time, especially in stopping bleeding. Doctors are looking at side effects and how it improves daily life.
Hemophilia A or Hemophilia BIreland - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, Randomized, Double-Blind Study of Tiragolumab Plus Atezolizumab Compared with Placebo Plus Atezolizumab in Participants with Completely Resected Stage IIB, IIIA, or Select IIIB, PD-L1 Positive, Non-Small Cell Lung Cancer who have received Adjuvant Platinum-Based Chemotherapy
This study looks at a new treatment for people with a certain type of lung cancer that has been removed by surgery. It compares two medicines, Tiragolumab and Atezolizumab, against Atezolizumab alone, to see if the new combination can help prevent the cancer from coming back.
Non-Small Cell Lung CancerIreland - Active not recruitingPHASE3
Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma
This study looks at a new drug, isatuximab, combined with standard treatments (lenalidomide and dexamethasone) for people with high-risk smoldering multiple myeloma. It aims to see if this combination can prevent the disease from getting worse compared to the standard treatments alone.
Plasma Cell MyelomaIreland - RecruitingPHASE3
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
This study is looking into a new drug, AZD5335, for women with advanced ovarian cancer that has become resistant to usual chemotherapy. It compares AZD5335 to existing treatments to see if it works better at controlling the cancer's growth.
Epithelial Ovarian CancerIreland - Active not recruitingPHASE1, PHASE2
Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors
This study is testing a new medicine called brenetafusp for people with certain advanced solid cancers that haven't responded to other treatments. It checks how safe and effective brenetafusp is, both alone and with other common cancer drugs.
Select Advanced Solid TumorsIreland - Active not recruitingPHASE2
A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)
This study is looking into a new medication called VHB937 for people with early-stage ALS. We want to see if it's safe and helps improve daily activities and breathing, compared to a dummy drug (placebo).
Amyotrophic Lateral Sclerosis (ALS)Ireland - Active not recruitingPHASE3
An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer
This study looks at a new immune-boosting medicine called Nivolumab for people who have had surgery for bladder or kidney drainage system cancer. It compares Nivolumab to a dummy drug to see if it's safe and helps stop the cancer from coming back.
Various Advanced CancerIreland - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2 Study of Tremelimumab (Day 1 only), Durvalumab (MEDI4736) and Trans-arterial catheter chemoembolization (TACE)in patients with advanced Hepatocellular Carcinoma (HCC)
This study is looking at a new combination of medicines and a treatment called TACE for people with advanced liver cancer. It aims to see if this combination can stop the cancer from growing for at least 6 months and if it's safe.
Advanced Hepatocellular Carcinoma (HCC)Ireland - Recruiting
Abbott Structural Heart Device Registry
This study looks at how well Abbott heart devices work in day-to-day hospital care. It helps make sure these devices are safe and effective for people with different heart conditions, like holes in the heart or valve problems, as they are used in real life.
Heart DiseasesASD - Atrial Septal DefectVSD - Muscular Ventricular Septal DefectPFO - Patent Foramen OvaleIreland - Recruiting
Affera Global Registry
This study looks at how well a device called the Affera Platform works for people with an irregular heartbeat called Atrial Fibrillation. It aims to gather real-world information on its safety and how effective it is in different patients after it's been approved for use.
Atrial FibrillationIreland - Active not recruitingPHASE2
(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis
This study is testing a new medicine, bezuclastinib, for people with certain types of mastocytosis (a rare blood disorder). It compares bezuclastinib with a dummy pill (placebo) to see if it safely helps reduce symptoms that aren't well controlled by current treatments.
SSMMastocytosis, IndolentMastocytosis, SystemicMastocytosisIreland - Active not recruitingPHASE3
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors
This study compares a new medicine, crovalimab, to an existing one, eculizumab, for people with a rare blood condition called PNH. It's looking at how safe and effective crovalimab is in patients already receiving similar treatments.
Paroxysmal Nocturnal HemoglobinuriaIreland - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Crossover Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Attacks in Adolescents and Adults with Hereditary Angioedema.
This study is testing a new soft capsule medicine for people with Hereditary Angioedema (HAE) to quickly stop attacks. It compares the new medicine, called deucrictibant, with a dummy capsule (placebo) and another existing medicine to see how fast it relieves symptoms.
Hereditary AngioedemaIreland - RecruitingPHASE2
A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD
This study is testing a new medicine, Verekitug, for people with moderate to severe COPD. It will check how well the medicine works and if it's safe. Participants will take Verekitug or a dummy pill alongside their usual COPD treatments.
Chronic Obstructive Pulmonary DiseaseIreland - RecruitingPHASE3
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
This study is looking at a new drug, camizestrant, for people with a common type of early breast cancer. It aims to see if camizestrant, compared to usual hormone therapy, can better prevent the cancer from coming back.
Breast Cancer, Early Breast CancerIreland - Ongoing, recruitingTherapeutic exploratory (Phase II)
REFRaME-O1: A Phase 2/3 Open-label Study Evaluating the Efficacy and Safety of Luveltamab Tazevibulin (STRO-002) versus Investigator’s Choice (IC) Chemotherapy in Women with Relapsed Platinum-resistant Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing Folate Receptor Alpha (FOLR1)
This study is for women with advanced ovarian (or related) cancer that has come back and isn't responding to platinum-based chemotherapy. Researchers are comparing a new treatment called Luveltamab Tazevibulin with standard chemotherapy to see if it works better and is safe.
Advanced Epithelial Ovarian Cancer (including Fallopian Tube or Primary Peritoneal cancers)Ireland - Ongoing, recruitingTherapeutic confirmatory (Phase III)
Efficacy and safety of cagrilintide s.c. in combination with semaglutide s.c. (CagriSema s.c.) once-weekly in participants with overweight or obesity and type 2 diabetes
This study is testing a new weekly injection combining two medicines, cagrilintide and semaglutide (called CagriSema), for people with type 2 diabetes who are also overweight or obese. It aims to see how well it helps with weight loss and managing blood sugar.
Overweight and obesity and type 2 diabetesIreland - RecruitingPHASE3
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
This study compares a new medicine, INCB123667, with standard chemotherapy for women with ovarian cancer that has grown despite platinum-based treatment and shows specific genetic changes. It aims to see if the new drug works better than current options.
Ovarian CancerIreland - Active not recruitingPHASE3
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
This study looks at a new drug, zanidatamab, combined with chemotherapy, and sometimes another drug called tislelizumab. It aims to see if this treatment works better and is safer than standard chemotherapy for advanced stomach and gullet cancers that have HER2.
Gastric NeoplasmsGastroesophageal AdenocarcinomaEsophageal AdenocarcinomaIreland - Active not recruitingPHASE3
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)
This study looks at a new drug combination, acasunlimab and pembrolizumab, for a type of lung cancer that has spread or is advanced. It compares this combination to a standard chemotherapy, docetaxel, in people who have already had certain other treatments.
PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLCIreland - Enrolling by invitationNA
Linguistically Tailored Health Messages to Encourage Plant-Based Food Choices in Adolescents
This study looks at how different types of messages can encourage young people aged 11-16 in the UK and Ireland to choose more plant-based foods. Researchers want to see if messages created specifically for an individual's chat style are better than general messages or no messages at all.
Food ConsumptionSustainable Food ConsumptionSustainable Healthy Eating BehaviourIreland - Active not recruitingPHASE3
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions
This study looks at a new drug, Luspatercept, for people with myelofibrosis and anaemia who need regular blood transfusions and are already taking a JAK2 inhibitor. We want to see if it helps reduce the need for transfusions.
Myeloproliferative DisordersMyelofibrosisPrimary MyelofibrosisPost-Polycythemia Vera MyelofibrosisIreland - Active not recruitingPHASE4
A Study on Safety and Effectiveness of Long-term Treatment With Vamorolone in Boys With Duchenne Muscular Dystrophy
This study looks at the long-term safety and effects of a medicine called vamorolone for boys with Duchenne Muscular Dystrophy. It includes boys who have already used vamorolone in other studies or special access programmes.
Duchenne Muscular DystrophyIreland - RecruitingPHASE2
WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
This study, called WISPer, is testing a new medicine called MTX-463 for Idiopathic Pulmonary Fibrosis (IPF). It's comparing MTX-463 to a dummy medicine (placebo) to see if it's safe and effective for people with this lung condition.
Idiopathic Pulmonary FibrosisIreland - RecruitingPHASE3
A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.
This study is looking at extra treatment with a drug called durvalumab after surgery for certain early-stage lung cancers. It aims to see if this additional medicine helps people stay cancer-free for longer after initial chemotherapy and surgery.
Non Small Cell Lung CancerIreland - RecruitingPHASE3
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
This study looks at new ways to treat advanced squamous non-small cell lung cancer. It combines standard treatment (Pembrolizumab, Carboplatin, Paclitaxel/Nab-paclitaxel) with a new drug, sac-TMT, to see if it helps people live longer.
Non-small Cell Lung CancerNSCLCIreland - Active not recruitingPHASE3
Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)
This study aims to see if adding the drug pembrolizumab to standard chemotherapy before and after surgery helps people with early-stage non-small cell lung cancer live longer and prevent the cancer from returning. It's a large study comparing this new approach with chemotherapy alone.
Non-small Cell Lung CancerIreland - RecruitingPHASE2
A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide in Adolescents (12 - 18 Years of Age) With Achondroplasia.
This study is looking at a new medicine called navepegritide for teenagers aged 12 to 18 with achondroplasia. We want to see if it helps them grow and if it's safe. It's compared to a dummy medicine over 52 weeks.
AchondroplasiaIreland - Recruiting
A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials
This study looks at how well new treatments called teclistamab and talquetamab work for people in the UK with a specific type of blood cancer called multiple myeloma, when these treatments are given outside of formal clinical trials. It's about understanding real-world results.
Relapsed/Refractory Multiple Myeloma (RRMM)Ireland - RecruitingPHASE3
A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation
This study looks at a new medicine called ziltivekimab for people with heart failure and inflammation. It aims to see if monthly injections of ziltivekimab can help, compared to a dummy medicine, over a few years.
Heart FailureIreland - RecruitingNA
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
This study compares two ways to remove stage II melanoma, using different-sized safety borders (1cm vs. 2cm). It aims to see if a smaller border is just as safe and improves quality of life, without increasing the chance of cancer returning.
Cutaneous Melanoma, Stage IIIreland - Active not recruitingPHASE3
A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy
This study looks at a new combination of drugs, ceralasertib and durvalumab, for people with advanced lung cancer that has grown after previous treatments. It compares this new combination to a standard chemotherapy drug, docetaxel, to see which works better and is safer.
Advanced or Metastatic Non-Small Cell Lung CancerIreland - RecruitingPHASE3
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
This study looks at new drug combinations for adults in the UK with a type of blood cancer called chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL). It compares new treatments with current ones to see which works best and is safest for patients whose cancer has come back or not responded to previous treatments.
Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaIreland - RecruitingPHASE3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
This study looks at the long-term safety and effectiveness of a cancer drug called pembrolizumab (and related treatments) for people with advanced cancers. It's for patients who are already receiving these treatments in other studies and want to continue.
Solid TumorsHematologic MalignanciesIreland - RecruitingPHASE3
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
This study looks at a new drug, acoramidis, for people who have a faulty gene that can cause a condition called ATTR. It aims to see if the drug can stop or slow down the disease from developing in people who don't yet have symptoms.
AmyloidosisAmyloid CardiomyopathyTransthyretin AmyloidosisCardiomyopathiesIreland - Active not recruitingPHASE3
A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer
This study is looking at a new treatment for early-stage lung cancer that can be removed with surgery. It combines standard chemotherapy with a newer drug called nivolumab. Researchers want to see if this combination helps people live longer without their cancer returning.
Carcinoma, Non-Small-Cell LungIreland - Active not recruiting
A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
This study looks at the long-term effects of a medicine called Humira for adults with a bowel condition called ulcerative colitis. It aims to see how well Humira works and if it's safe over a long time when used as doctors usually prescribe it.
Ulcerative Colitis (UC)Ireland - RecruitingPHASE3
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
This study looks at combining two medicines, vedolizumab and upadacitinib, for adults with moderate to severe Crohn's Disease. It aims to see if this combination better reduces bowel inflammation and ulcers compared to vedolizumab alone, and to check its safety.
Crohn's DiseaseIreland - RecruitingPHASE2
Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
This study is testing a new medicine, Imeroprubart, for adults with a nerve condition called Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Researchers want to see if it's safe and helps improve symptoms compared to a dummy treatment.
Chronic Inflammatory Demyelinating PolyneuropathyIreland - Recruiting
Lysosomal Acid Lipase (LAL) Deficiency Registry
This study is gathering information on a rare genetic condition called LAL Deficiency. It aims to understand the disease better and improve care for affected individuals, from babies to adults. It's a worldwide effort to collect health data over time.
Lysosomal Acid Lipase DeficiencyCholesterol Ester Storage DiseaseWolman DiseaseAcid Cholesteryl Ester Hydrolase Deficiency, Type 2Ireland